Study on the Relationship between the Level of Soluble HLA-E Molecules in Plasma and Gene Polymorphism and Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.02.004
- Author:
Li-Yan SUN
1
;
Yun-Ping XU
2
Author Information
1. Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen 518035, Guangdong Province, China.
2. Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen 518035, Guangdong Province, China,E-mail: yunpingxu1982@qq.com.
- Publication Type:Journal Article
- Keywords:
genotype;
leukemia;
lymphoid leukemia;
myeloid leukemia;
soluble HLA-E molecule
- MeSH:
Genotype;
Histocompatibility Antigens Class I/genetics*;
Humans;
Leukemia/genetics*;
Polymorphism, Genetic
- From:
Journal of Experimental Hematology
2022;30(2):346-350
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the relationship between the level of soluble HLA-E (sHLA-E) molecules in plasma and gene polymorphism and leukemia in Shenzhen of China.
METHODS:Enzyme-linked immunosorbent assay was used to detect sHLA-E level in plasma of 103 leukemia patients and 113 healthy blood donors. PCR-SBT was used to identify the HLA-E genotype of 73 leukemia patients and 76 healthy blood donors.
RESULTS:The level of plasma sHLA-E of 103 leukemia patients was significantly higher than that of 113 healthy blood donors (P<0.001); And the level of plasma sHLA-E in 77 myeloid leukemia patients was also significantly higher (P<0.001). The percentage of patients with plasma sHLA-E concentration of 0-199 ng/ml in leukemia and myeloid leukemia patients was 37.86% and 32.47%, respectively, which was significantly lower than 53.98% of healthy donors, the difference was statistically significant (P<0.05, P<0.01); While, when the plasma sHLA-E concentration was more than 400 ng/ml, the percentage was 33.01% and 36.36%, respectively, which was significantly higher than 13.28% of healthy donors, the difference was also statistically significant (P=0.001, P<0.001). There was no significant difference in the level of plasma sHLA-E among different HLA-E genotypes (P>0.05), whether healthy blood donors or leukemia patients.
CONCLUSION:The level of plasma sHLA-E in patients with leukemia (especially myeloid leukemia) is significantly higher than that of healthy blood donors, but different HLA-E genotypes do not affect the level of plasma sHLA-E. A cut-off value for the concentration of plasma sHLA-E (recommended risk value >400 ng/ml) can be set to assess the risk of certain pre-leukemia patients.
